Increasing healthcare expenditure and the availability of effective treatment options have led to an increase in the median age worldwide. The WHO, CDC, and European Centre for Disease Prevention and Control, among other regulatory bodies, are actively recording incidence & prevalence data to counter the disease systematically. These bodies work together with local governments to achieve overall control of the treatment and management of this disease.
The Global Influenza Program (GIP) is one initiative the WHO undertook to provide technical support, strategic guidance, and coordination activities concerning zoonotic, pandemic, and seasonal flu cases. Such initiatives are expected to boost Influenza Diagnostics market growth during the forecast period.
Influenza Diagnostics Market size was valued at USD 1.1 Billion in 2023 and is poised to grow from USD 1.14 Billion in 2024 to USD 1.51 Billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).
COVID- 19 has had a significant impact on the influenza diagnostics market across the globe. Many manufacturing facilities have ceased or closed because of the nation-wide lockdowns. Unfavorable regulations and guidelines changes of many disease diagnostics are hampering the flu diagnostic medium market. Supply chain disruptions in and responses to the spread of COVID- 19 are expected to have an impact. Besides, COVID- 19 and influenza have multiple things in common – Both of them are contagious viruses and also show similar symptoms of respiratory illness. Hence, it is mandatory to test for influenza, whenever COVID-19 affects the respiratory system of a patient. This is creating an increasing testing for influenza.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/influenza-diagnostics-market
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Influenza Diagnostics Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Influenza Diagnostics Market is segmented by Product, Test, End User and Region.
Based on Product, the market is segmented into Test kit and Reagents, Instruments, Other Products.
Based on Test, the market is segmented into Molecular Diagnostic Test (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification, Tests), Transcription Mediated Amplification Based Assay, Loop Mediated Isothermal Amplification Based Assay, Nucleic Acid Sequence based Amplification Tests, Traditional Diagnostics Tests (Rapid Influenza Diagnostic Test, Viral Culture Test, Direct Fluorescent Antibody Test, Serological Tests).
Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals and Clinics, Others.
Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Influenza Diagnostics Market – Regional Analysis:
North America is dominating the Influenza Diagnostics market with the largest market share. The North American region dominated the diagnostic market in 2023 which was mainly due to the government’s support for high-quality healthcare, increase in focus of influenza outbreak, and the high buying power.
The U.S. was the largest revenue contributor to the North American market in 2023. This is mainly because the U.S. market is expected to grow due to the well-established healthcare infrastructure and increase in programs for influenza diagnostics. These factors are increasing the growth of the influenza diagnostics market in the North America region.
The Asia Pacific is poised for substantial growth during the forecast period. This is due to the fact that in countries such as India and China, where there is increasing awareness of diseases and an increasing incidence of cancer & diabetes, there are also growth opportunities.
Top Market Players in Influenza Diagnostics Market are:
Thermo Fisher Scientific (US)
Becton, Dickinson and Company (US)
F. Hoffmann-La Roche AG (Switzerland)
Hologic, Inc. (US)
Abbott Laboratories, Inc. (US)
DiaSorin (Italy)
QIAGEN N.V. (Netherlands)
Fujirebio Diagnostics, Inc. (Japan)
Meridian Bioscience, Inc. (US)
Luminex Corporation (US)
Seegene Inc. (South Korea)
Bio-Rad Laboratories, Inc. (US)
Alere Inc. (US)
GenMark Diagnostics, Inc. (US)
Roche Diagnostics (Switzerland)
BioMérieux SA (France)
Cepheid (US)
SD Biosensor (South Korea)
Acon Laboratories, Inc. (US)
Inverness Medical Innovations, Inc. (US)
Influenza Diagnostics Market Recent Developments:
Becton, Dickinson and Company got the U.S. FDA clearance for a respiratory viral panel in August 2023 for the identification of patients infected by flue and respiratory syncytial virus.
Lucira COVID-19 & Flu Home Test, developed by Pfizer Inc. was cleared in February 2023 by the U.S. FDA emergency use of authorization approval to diagnose influenza viruses A and B. The test is an over the counter at-home diagnostic test.
In October 2022, the European and North American regulatory bodies provided Hologic Inc. approval ti launch its Aptima SARS-CoV-2/Flue test.
You may Also Like
https://medium.com/@kathan.trivedi/th%E1%BB%8B-tr%C6%B0%E1%BB%9Dng-n%C6%B0%E1%BB%9Bc-t%C4%83ng-l%E1%BB%B1c-xu-h%C6%B0%E1%BB%9Bng-c%C6%A1-h%E1%BB%99i-t%C4%83ng-tr%C6%B0%E1%BB%9Fng-v%C3%A0-tri%E1%BB%83n-v%E1%BB%8Dng-t%C6%B0%C6%A1ng-lai-e5a65c6741e3
https://medium.com/@kathan.trivedi/th%E1%BB%8B-tr%C6%B0%E1%BB%9Dng-organ-on-chip-xu-h%C6%B0%E1%BB%9Bng-c%C6%A1-h%E1%BB%99i-t%C4%83ng-tr%C6%B0%E1%BB%9Fng-v%C3%A0-tri%E1%BB%83n-v%E1%BB%8Dng-t%C6%B0%C6%A1ng-lai-eca6fd0962ba
Forward-Looking Insights
The Influenza Diagnostics Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]”
